New data has been revealed in support of Novartis’ Cosentyx (secukinumab) in the treatment of moderate-to-severe plaque psoriasis, demonstrating the drug delivered greater quality of life improvements compared to Janssen’s Stelara (ustekinumab) after 16 weeks of treatment.
The data showed that 68.4% of patients receiving Cosentyx experienced no impact of skin disease on their quality of life after 16 weeks of treatment, compared to 55.9% of those receiving Stelara.
